New Technology Developed to Diagnose Cancer Cells
|
By LabMedica International staff writers Posted on 04 Aug 2014 |

Image: Microscopic analysis system automatically acquires up to eight slides with immunohistochemically stained sections and performs quantitative analysis of staining intensities (Photo courtesy of TissueGnostics).
Patient tumors can be analyzed for aberrant activations of core cancer pathways by monitoring based on biomarker expression which ensures efficient treatment in targeted therapy.
Standard evaluation of cancer specimen by immunohistochemistry is frequently impeded by its dependence on subjective interpretation, showing considerable intra- and inter-observer variability and the certainty of the diagnosis depends greatly on the individual pathologist.
Scientists at the Medical University of Vienna (Austria) working with their colleagues from other institutes, used both human liver specimens and a mouse model to test quantitative image analysis tools. They used immunohistochemistry to identify deletion of the transcription factors Signal Transducer and Activator of Transcription 5 (Stat5ab) in the liver as well Transcription factor jun-B (Junb) deletion in a T-cell lymphoma model. They quantified the expression of total or activated STAT5AB or JUNB protein by Western Blots and detection was accomplished using an electrochemiluminescence detection system (Amersham Biotech; Amersham, UK).
The technology-platform of TissueGnostics GmbH (Vienna, Austria) provides tools to quantify protein expression levels on immunohistochemically stained tissue slides or cell preparations using the company’s proprietary HistoQuest. The software programs are based on single cell detection by identification of nuclear structures. The software uses certain algorithms and highly sensitive digital photography, enabling it to represent the matrix of cells and the cell nucleus better than under the microscope. STAT5 plays an important role in the development of leukemia and liver cancer. The JUNB gene is involved in the development of tumors in lymph gland tissue.
Nuclear signals were distinguished from cytoplasmic expression and translocation of the transcription factors from the cytoplasm to the nucleus and were reliably detected and quantified using image analysis. The investigators demonstrated that image analysis supported pathologists to score nuclear STAT5AB expression levels in immunohistologically stained human hepatocellular patient samples and decreased inter-observer variability. The scientists investigated and analyzed 30 liver cell carcinomas and were able to classify them into categories ranging from "negative" to "strongly positive" using the software.
Lukas Kenner MD, the senior author of the study, said, “The new program of course does not make pathologists redundant, however it is a supplementary method that considerably increases diagnostic certainty. Cancer therapies are expensive. This new software will also help us to assess more effectively where expensive therapy is justified, but also which cases do not need it, thereby also sparing the patient.” The study was published on July 11, 2014, in the journal Public Library of Science ONE.
Related Links:
Medical University of Vienna
Amersham Biotech
TissueGnostics
Standard evaluation of cancer specimen by immunohistochemistry is frequently impeded by its dependence on subjective interpretation, showing considerable intra- and inter-observer variability and the certainty of the diagnosis depends greatly on the individual pathologist.
Scientists at the Medical University of Vienna (Austria) working with their colleagues from other institutes, used both human liver specimens and a mouse model to test quantitative image analysis tools. They used immunohistochemistry to identify deletion of the transcription factors Signal Transducer and Activator of Transcription 5 (Stat5ab) in the liver as well Transcription factor jun-B (Junb) deletion in a T-cell lymphoma model. They quantified the expression of total or activated STAT5AB or JUNB protein by Western Blots and detection was accomplished using an electrochemiluminescence detection system (Amersham Biotech; Amersham, UK).
The technology-platform of TissueGnostics GmbH (Vienna, Austria) provides tools to quantify protein expression levels on immunohistochemically stained tissue slides or cell preparations using the company’s proprietary HistoQuest. The software programs are based on single cell detection by identification of nuclear structures. The software uses certain algorithms and highly sensitive digital photography, enabling it to represent the matrix of cells and the cell nucleus better than under the microscope. STAT5 plays an important role in the development of leukemia and liver cancer. The JUNB gene is involved in the development of tumors in lymph gland tissue.
Nuclear signals were distinguished from cytoplasmic expression and translocation of the transcription factors from the cytoplasm to the nucleus and were reliably detected and quantified using image analysis. The investigators demonstrated that image analysis supported pathologists to score nuclear STAT5AB expression levels in immunohistologically stained human hepatocellular patient samples and decreased inter-observer variability. The scientists investigated and analyzed 30 liver cell carcinomas and were able to classify them into categories ranging from "negative" to "strongly positive" using the software.
Lukas Kenner MD, the senior author of the study, said, “The new program of course does not make pathologists redundant, however it is a supplementary method that considerably increases diagnostic certainty. Cancer therapies are expensive. This new software will also help us to assess more effectively where expensive therapy is justified, but also which cases do not need it, thereby also sparing the patient.” The study was published on July 11, 2014, in the journal Public Library of Science ONE.
Related Links:
Medical University of Vienna
Amersham Biotech
TissueGnostics
Latest Pathology News
- AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
- New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
- Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
- Review Highlights Progress and Validation Needs for AI in Digital Pathology
- Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
- AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Channels
Clinical Chemistry
view channel
Skin Swab Research Identifies Metabolic Changes Linked to Parkinson’s Disease
Parkinson’s disease can be difficult to diagnose before movement symptoms appear, highlighting the need for earlier detection methods. Researchers have explored whether metabolic changes in sebum, the... Read more
AI Predicts Kidney Stone Composition From Routine Urine Tests
Kidney stones are a common and painful condition, affecting approximately one in 11 Americans, with lifetime recurrence rates of 60% to 80%. Identifying stone composition is important for guiding treatment... Read moreMolecular Diagnostics
view channel
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more
Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
Fapon showcased its AI-engineered enzymes, reverse transcription technologies, and nucleic acid library preparation solutions at the Association for Molecular Pathology (AMP) 2026 Annual Meeting &... Read moreAMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more
AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







